NAT2 and age-related macular degeneration: However, a further detailed analysis of NAT2 patient data revealed that individuals with high levels of red blood cell membrane (RBCM) EPA + DHA (good marker for LCPUFAs) are at reduced risk to develop nAMD, suggesting that RBCM EPA + DHA can be a clinically useful biomarker of AMD [54].